Equity Research | Desk Note

Island Pharmaceuticals Ltd (ASX: ILA)

Galidesivir Cleared for Compassionate Use in the Bundibugyo Ebola Outbreak

7 July 2026 | Analyst: Nathan Graves

Company Snapshot

Company	Island Pharmaceuticals Ltd (ASX: ILA)
Lead asset	Galidesivir, a clinical-stage broad-spectrum antiviral molecule
Lead indication	Marburg virus disease
Secondary indications	Ebola, Dengue Fever
Shares on issue	296m
Price (open 7 July 2026)	$0.52
Market Cap (open 7 July 2026)	$154m
Cash (31 March 2026)	$14m

Island Pharmaceuticals has secured all regulatory and ethics approvals to supply its antiviral Galidesivir for compassionate use in patients infected during the current Bundibugyo Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda. The drug will be administered under the World Health Organization's MEURI framework (Monitored Emergency Use of Unregistered and Investigational Interventions), a structured pathway that allows access to unapproved therapies during emergencies while investigators prospectively collect clinical, safety and virology data.

Island's cost is limited to supplying the drug; the program is fully funded by the Uganda Government and supporting institutions, therefore non-dilutive for shareholders. There are currently no approved therapeutics or vaccines specifically for Bundibugyo Ebola or Marburg virus, which is the basis for the emergency-access route.

The European Centre for Disease Prevention and Control reported 1,561 confirmed cases and 506 confirmed deaths in DRC as of 5 July 2026 indicating a fatality rate of >30%.

Strategic Rationale

Non-dilutive: The program is fully funded by the Uganda Government and supporting institutions; Island's cost is limited to supplying the drug.

Dual pathway: Real-world human data (MEURI) can run alongside the controlled animal-model program under the FDA Animal Rule.

Could follow the path of two previously approved drugs: The two approved Ebola drugs Inmazeb and Ebanga were approved based on human clinical data gathered during active outbreaks and have reportedly generated >US$1bn through government stockpile.

Manufacturing readiness: Recent GMP campaign lets Island supply clinical-grade drug quickly. Island guides they will have Galidesivir available for use prior to the end of CY26.

Relationships: Deepens ties with African outbreak investigators (ACCEPT-Africa, IDI Makerere, Uganda MoH), useful for any future outbreak work.

Prenzler Group Pty Ltd ABN 77 621 100 730 | Authorised Rep of AFSL 456663
Suite 1 Level 12/25 Bligh St, Sydney NSW 2000, Australia
www.prenzlergroup.com.au

Catalysts to Watch

Catalyst	Timing	Significance
Galidesivir deployment (Ebola)	Within CY26	First supply of GMP-grade drug to treatment sites, MEURI use to begin
Early human data (Ebola)	H2 CY26+ (indicative)	Prospective clinical, safety and virological data from treated patients
Dose optimisation study commences (Marburg)	Expected next quarter	The next active efficacy step for Galidesivir under the Marburg Animal Rule pathway
Dose optimisation topline results (Marburg)	H2 CY26	Key near-term value driver, expected to inform the dose and design of the pivotal confirmatory efficacy study
Pivotal confirmatory efficacy study design (Marburg)	Following dose optimisation	Converts the dose optimisation output into the study likely needed for potential FDA approval
Pivotal study execution (Marburg)	CY2027	Central study for the potential Animal Rule approval package
FDA submission (Marburg)	CY2027	Dependent on successful dose optimisation, pivotal efficacy, human safety, manufacturing and regulatory package

Indicative timing only. Events may be delayed, modified or may not occur.

Island gains a route to generate human data at effectively no direct cost, while keeping its primary Animal-Rule pathway intact. If even modest supportive data emerges, comparisons can be drawn to Ebanga and Inmazeb which were approved on efficacy from real-world data, and subsequently procured into national stockpiles. In 2023 Emergent BioSolutions secured a 10-year contract from the Biomedical Advanced Research and Development Authority (BARDA) to supply Ebanga worth over US$700m.

Disclosure: Prenzler Group directors and employees own fully paid ordinary shares in Island Pharmaceuticals Ltd ASX: ILA

General Advice Warning
Please note that any advice given by Prenzler Group Pty Ltd or authorised representatives (Prenzler Group) is GENERAL advice, as the information or advice given does not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument. Prenzler Group Pty Ltd | ABN 77 621 100 730 | Authorised Representative of AFSL 456663.

Disclaimers
Prenzler Group does not warrant the accuracy of any information it sources from others. Prenzler Group provides a report as an opinion held at a point in time about an investment or sector. Prenzler Group has no obligation to update the opinion unless you are a client of Prenzler Group. Assessment of risk can be subjective. Historical information may not translate into future performance. Portfolios of investments need to be well diversified and the risk appropriate for the investor. Prenzler Group does not stand behind the capital value or performance of any investment. To the fullest extent permitted by the law, Prenzler Group disclaim any liability for any loss or damage arising from the use of, or the reliance on, any information within the advice whether or not caused by any negligent act or omission of Prenzler Group. Overseas investors acknowledge that Prenzler Group has not solicited their business.

Confidentiality Notice
This email (and any attachments) is intended only for the addressee and may contain information which is confidential and privileged. If you are not the addressee you may not use, disseminate or copy this information. If you have received this information in error please notify us immediately and destroy this email and attachments. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person.

Prenzler Group Pty Ltd ABN 77 621 100 730 | Authorised Rep of AFSL 456663
Suite 1 Level 12/25 Bligh St, Sydney NSW 2000, Australia
www.prenzlergroup.com.au